Loading…
Alvotech is projected to rise to $4.28 by 2027, a +4% move from its current price of $4.12. ALVO is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $3.94 | $4.12 | $4.31 | +0.02% |
| Aug 3 | $3.87 | $4.12 | $4.39 | +0.05% |
| Aug 4 | $3.82 | $4.12 | $4.45 | +0.07% |
| Aug 5 | $3.78 | $4.12 | $4.50 | +0.10% |
| Aug 6 | $3.74 | $4.13 | $4.55 | +0.12% |
| Aug 7 | $3.70 | $4.13 | $4.60 | +0.15% |
| Aug 8 | $3.67 | $4.13 | $4.64 | +0.17% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.67 | $4.13 | $4.64 | +0.17% |
| Week 2 | $3.51 | $4.13 | $4.88 | +0.35% |
| Week 3 | $3.38 | $4.14 | $5.07 | +0.52% |
| Week 4 | $3.29 | $4.15 | $5.24 | +0.70% |
| Week 5 | $3.20 | $4.16 | $5.39 | +0.87% |
| Week 6 | $3.13 | $4.16 | $5.54 | +1.05% |
| Week 7 | $3.06 | $4.17 | $5.68 | +1.22% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ankylosing spondylitis ulcerative colitis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.
In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product for the treatment of adult patients with moderate to severe ulcerative colitis and moderate to severely active Crohn's disease; AVT23, a biosimilar to Xolair to treat allergic asthma, chronic spontaneous urticaria (CSU), and nasal polyp; and AVT33, a biosimilar to Keytruda product which is in early phase development. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.
ALVO trades with a current price of $4.12 and a market cap of $1.39B, ranking 2195 by market capitalization. The stock sits in a healthcare-focused space, with a portfolio of biosimilar candidates and a pipeline that includes AVT33 in early phase development. The price forecast indicates potential upside over the coming years, with a progression of average prices from 2026 through 2050 and corresponding return profiles.
A major floor 34.3% below — a decisive break under it would weaken the trend.
The nearest floor, 25.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 17.2% above — clearing it would confirm fresh momentum.
Key ALVO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ALVO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.48 | Buy | $3.62 | Buy |
| MA 10 | $3.38 | Buy | $3.48 | Buy |
| MA 20 | $3.38 | Buy | $3.45 | Buy |
| MA 50 | $3.55 | Buy | $3.52 | Buy |
| MA 100 | $3.52 | Buy | $3.78 | Buy |
| MA 200 | $4.47 | Sell | $4.73 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 67.59 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 320.35 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.07 | Buy |
| ROC (12) | 21.89 | Buy |
| Bollinger %B (20,2) | 1.32 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.35 | Sell |
| Awesome (5,34) | -0.06 | Sell |
| Ultimate (7,14,28) | 78.86 | Sell |
| Momentum (10) | 0.66 | Buy |
| Aroon Osc (25) | 20.00 | Buy |
| Hull MA (9) | 3.72 | Buy |
| ADX (14) | 16.02 | Neutral |
| ATR (14) | 0.14 | Info |
Technically, the near term shows a bullish tilt, with RSI14 at 70 and a sentiment labeled BULLISH. The 50-day simple moving average sits at $3.55, while the 200-day moving average is at $4.47, framing near-term resistance near the current price.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.00 | $4.12 | $6.00 | 0% | Neutral | |
| $3.23 | $4.28 | $6.11 | +4% | Neutral | |
| $3.32 | $4.63 | $6.99 | +12% | Neutral | |
| $3.08 | $4.48 | $7.05 | +9% | Neutral | |
| $3.40 | $5.12 | $8.35 | +24% | Bullish | |
| $4.67 | $7.28 | $12.25 | +77% | Bullish | |
| $4.46 | $7.19 | $12.43 | +74% | Bullish | |
| $4.32 | $7.18 | $12.72 | +74% | Bullish | |
| $4.57 | $7.81 | $14.15 | +90% | Bullish | |
| $4.12 | $7.25 | $13.41 | +76% | Bullish | |
| $5.41 | $10.89 | $21.91 | +164% | Bullish | |
| $11.77 | $26.15 | $59.37 | +535% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.00 | $4.12 | $5.17 | +0.00% |
| September 2026 | $3.42 | $4.12 | $5.16 | +0.11% |
| October 2026 | $3.46 | $4.21 | $5.36 | +2.18% |
| November 2026 | $3.67 | $4.51 | $5.82 | +7.10% |
| December 2026 | $3.71 | $4.60 | $6.00 | +1.93% |
Click any year to see its month-by-month ALVO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Alvotech's 2026 outlook centres on $4.12, within a $3.00 to $6.00 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, ALVO could reach as high as $6.11, with a base case around $4.28 and support toward $3.23 — roughly +4% from $4.12. Price action looks broadly range-bound.
Expect ALVO to range from $3.32 to $6.99 through 2028. The $4.63 average target implies a +12% move from current prices. That is up +8% on the projected 2027 average. A consolidation phase looks the most probable path here.
The ALVO price prediction for 2029 points to an average of $4.48 (low $3.08, high $7.05) — a potential gain of +9% on today's $4.12. Price action looks broadly range-bound.
In 2030, ALVO is projected to trade between $3.40 and $8.35, averaging $5.12 — a potential gain of +24% from today's $4.12. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Alvotech's 2031 outlook centres on $7.28, within a $4.67 to $12.25 range. That is up +42% on the projected 2030 average. That marks a +77% change versus current levels. Momentum favours further upside here.
By 2032, ALVO could reach as high as $12.43, with a base case around $7.19 and support toward $4.46 — roughly +74% from $4.12. Buyers look set to stay in control over this stretch.
Expect ALVO to range from $4.32 to $12.72 through 2033. The $7.18 average target implies a +74% move from current prices. That is 0% versus the projected 2032 average. Momentum favours further upside here.
The ALVO price prediction for 2034 points to an average of $7.81 (low $4.57, high $14.15) — a potential gain of +90% on today's $4.12. Buyers look set to stay in control over this stretch.
In 2035, ALVO is projected to trade between $4.12 and $13.41, averaging $7.25 — a potential gain of +76% from today's $4.12. That is -7% versus the projected 2034 average. Momentum favours further upside here.
Alvotech's 2040 outlook centres on $10.89, within a $5.41 to $21.91 range. That is up +50% on the projected 2035 average. That marks a +164% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, ALVO could reach as high as $59.37, with a base case around $26.15 and support toward $11.77 — roughly +535% from $4.12. Momentum favours further upside here.
Investing $1,000 in ALVO today (≈ 242.718447 ALVO) could be worth
$6,347.57
+$5,347.57 (+535%) by 2050 · US Dollar
Based on the average projected ALVO price of $26.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ALVOwould be worth at today's price.
$1,000 invested in ALVO on Jul 31, 2025 (≈ 110.375271 ALVO) would be worth
$454.75
-$545.25 (-54.5%) today · 0.45× · US Dollar
Based on a ALVO entry price of $9.06 vs. today's $4.12.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.06 | $1,346.41 | +34.6% |
| 1 month ago | $3.58 | $1,150.84 | +15.1% |
| 3 months ago | $3.46 | $1,190.75 | +19.1% |
| 6 months ago | $5.32 | $774.44 | -22.6% |
| 1 year ago | $9.06 | $454.75 | -54.5% |
| All time (4.1y) ago | $11.19 | $368.19 | -63.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ALVO forecast.
Our base-case forecast reaches $8.20 around 2040.
Implied market cap at $8.20: $2.77B
The multi-year outlook envisions meaningful upside, with the 2030 average price at $5.12 and a 24.2% ROI, followed by continued strength into the 2040s and 2050s. In 2040, the average price is projected at $10.89 with a 164.2% ROI, and by 2050 the average price could reach $26.15 with a 534.8% ROI. The forecast signals a bullish trajectory through 2031–2050, supported by increasingly higher average prices and robust potential returns, albeit with uncertainty inherent in any forecast.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $5.12 with min $3.40, max $8.35 and a ROI of 24.2%, with sentiment BULLISH.
The forecast outlines a bullish trajectory through 2030–2050, with 2030 avg $5.12, 2040 avg $10.89, and 2050 avg $26.15; ROIs reach 24.2%, 164.2%, and 534.8% respectively, though these are estimates and not guarantees.
Yes, the forecast shows 2040 with an avg price of $10.89 and a ROI of 164.2%, indicating potential to exceed $10 over the horizon.
By 2050, the avg price is projected at $26.15 with a ROI of 534.8%, and the range for 2050 is $11.77 to $59.37, with sentiment staying BULLISH.
Current price is $4.12 and market cap is $1.39B.
Alvotech Community Discussion
0Share your Alvotech price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.